FTSE MIB
34.492,41 +44,84 (+0,13%) Dow Jones
38.686,32 +574,84 (+1,51%) Nasdaq
16.735,02 -2,06 (-0,01%) Nikkei 225
38.487,90 +433,77 (+1,14%) Petrolio
77,18 -0,73 (-0,94%) Bitcoin EUR
62.361,97 +479,60 (+0,78%)
NTLA Oct 2024 40.000 put
| Chiusura precedente | 15,50 |
| Aperto | 15,20 |
| Denaro | 16,80 |
| Domanda | 18,70 |
| Prezzo d'esercizio | 40,00 |
| Scadenza | 2024-10-18 |
| Min-Max giorno | 15,20 - 15,72 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 4 |
GlobeNewswireIntellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially
- GlobeNewswire
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collabo
- GlobeNewswire
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Completed identification of all patients for the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) Plans to initiate a global pivotal Phase 3 study of NTLA-2002 as early as Q3 2024, subject to regulatory feedback On track to submit IND application in September for a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedbackPlans to present addi
